Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Ashok, M.
- Current and Future Trends of Drugs used in Osteoporosis
Abstract Views :294 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, P.E.S. College of Pharmacy, Hanumanthanagara, Bangalore-560050, IN
1 Department of Pharmacology, P.E.S. College of Pharmacy, Hanumanthanagara, Bangalore-560050, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 3, No 6 (2011), Pagination: 329-333Abstract
Osteoporosis represents a weakening of bone tissue due to an imbalance in the dynamic processes of bone formation and bone resorption that are continually ongoing within bone tissue. Most currently available osteoporosis therapies are antiresorptive agents. Promising new drugs are currently under investigation by the FDA for the treatment of osteoporosis. Majority of the drugs used in osteoporosis are antiresorptive agents. These drugs act by inhibiting osteoclastic bone resorption and thus slowing the loss of bone mass. However these drugs do not stimulate new drug formation and does not increase true bone mass. The only FDA approved bone anabolic agent is PTH. It is the most beneficial agent for the patients with very low bone mass. Clinical trials are undergoing for denosumab. One of the new drug strontium ranelate acts by stimulating the bone formation and inhibiting bone resorption. More recent research indicates that dietary sources of phytoestrogens may increase osteoprotegerin production and help prevent bone loss and bone resorption; however, rigorous data are needed before clinical recommendations can be made. This review discusses the use of currently available agents as well as highlighting emerging agents expected to bring significant changes to the approach to osteoporosis therapy in the near future.Keywords
Bone Resorption, Antiresorptive Agent, Bone Anabolic Agent, Osteoprotegerin.
References
- Goodman, Gilman. Pharmacological basis of therapeutics. 11th ed: McGraw-Hill. 1662-1672.
- Burger H, van Daele PLA, Algra D,et al. Vertebral deformities as predictors non-vertebral fractures. BMJ. 1994; 309:991-2.
- Shirwaikar Anniea, Prabhua R G, Malini S. Activity of Wedelia calendulacea Less. in post-menopausal osteoporosis. Phytomedicine. 2006; 13:43–8.
- Yan-Bin W, Cheng-Jian Z, Lu-Ping Q, Lian-Na S, Ting H, Lei J, et al. Antiosteoporotic Activity of Anthraquinones from Morinda officinalis on Osteoblasts and Osteoclasts. Molecules. 2009; 14:573-83.
- Valerie CS, Tina Sanders. Essentials of Anatomy and Physiology. 5 ed. New York: F. A. Davis Company; 2007.
- Aaron JE, Shore PA, Shore RC, Beneton M, Kanis JA. Trabecular architecture in women and men of similar bone mass with and without vertebral fracture. Bone. 2000; 27:277-82.
- Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354:2250-61.
- Raisz L. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest. 2005; 115:3318-25.
- Khosla S, Riggs BL, Atkinson EJ. Effects of sex and age on bone microstructure at the ultradistal radius: A population-based noninvasive in vivo assessment. J Bone Miner Res. 2006; 21:124-31.
- Guyton Human physiology and mechanisms of disease. 5th ed. 599-04.
- Tripathi KD. Essentials of Medical pharmacology. 6th ed. Jaypee Brother's medical publishers (P) Ltd. New Delhi; 293-33.
- Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs. 1991; 42:919-44.
- Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986; 38:342-49.
- Domb AJ, Tabata Y, Ravikumar MNV, Farber S. Nanoparticles of pharmaceutical applications. 74-98.
- Bauss F, Dempster DW. Effects of ibandronate on bone quality: Preclinical studies. Bone. 2007; 40:265-73.